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Aims: Ventricular arrhythmias are common after acute myocardial infarction (AMI). Endothelin (ET) is a mediator
of microvascular dysfunction and cardiac remodeling with arrhythmogenic potential. The aim of this study
was to assess safety and feasibility of selective ET-A receptor blockade in ST-elevation acute coronary syndrome
(STE-ACS) within a larger randomized trial.
Main methods: Patients with posterior-wall STE-ACS were randomly assigned to receive intravenous BQ-123 at
400 nmol/min or placebo over 60 min, starting immediately prior to primary percutaneous coronary interven-
tion. Twenty-four hour Holter recordings were performed during hospitalization for STE-ACS and after
6–8 weeks. The predeﬁned primary endpoint was the documentation of ventricular tachycardia and/or late
potentials at follow-up.
Key ﬁndings: There was no signiﬁcant difference in the predeﬁned primary endpoint at 45 (33–62) days (0/16
(0%) in BQ-123 treated patients vs. 1/14 (7%) in the placebo group, p = 0.465). At 2 (1–3) days, an increase
in the total number of supraventricular extrasystoles (SVES)/24 h in patients randomized to BQ-123
(45 (17–165) beats vs. 11 (5–72) beats in placebo treated patients, p = 0.025) occurred. This increase was
also observed at 45 days (105 (37–216) beats vs. 11 (3–98) beats in placebo treated patients, p = 0.037).
There was no signiﬁcant difference regarding other rhythmologic secondary endpoints between the two groups.
Signiﬁcance: Based on the analysis of long-term ECG data, short-term administration of BQ-123 after AMI was
safe. Because of the small sample size, no ﬁrm conclusion regarding antiarrhythmic efﬁcacy can be drawn.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Ventricular arrhythmias represent a severe and common form of
complications after acute myocardial infarction (AMI). While sudden
cardiac death, mostly caused by ventricular tachycardia or ventricular
ﬁbrillation (VF), poses an immediate risk in the early phase, chronic
phase arrhythmogenesis develops in a proportion of patients (Adabag
et al., 2008; Bloch Thomsen et al., 2010; Camm et al., 2004; Solomon
et al., 2005). The most important factor leading to ventricular arrhyth-
mias in the chronic phase is the size of the infarcted area (Roberts
et al., 1975; Crawford et al., 2010), which is determined, amidst otherdicine II, Division of Cardiology,
1090 Vienna, Austria. Tel.: +43
g).
. This is an open access article underfactors, by ischemia/reperfusion injury; large infarcts result in ventricu-
lar remodeling and myocardial substrate formation.
Endothelin-1 (ET-1), one of the most potent known vasocon-
strictors, was found in acute coronary thrombi and was signiﬁcantly
elevated in re-perfused ischemic myocardium (Adlbrecht et al.,
2007; Keltai et al., 2004; Tonnessen et al., 1995). Additionally, ET-1
was identiﬁed as a predictor of long-term clinical outcome after
AMI (Khan et al., 2007). When intravenously administered to dogs,
it induced ventricular tachycardia (Toth et al., 1995). It was shown
that ET-1 dose-dependently increases the norepinephrine release
in the myocardium after ischemia/reperfusion injury and thereby
increases the incidence of VF in isolated guinea pig hearts (Isaka
et al., 2007).
ET receptor blockade was demonstrated to reduce infarct size and
exert antiarrhythmic effects in some animal models, however, it is un-
clear whether a protective effect exists in patients (Alberola Aguilar
et al., 2000; Baltogiannis et al., 2005; Crockett et al., 2001; Gelzer et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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ingly, when studied in the setting of ischemic arrhythmia in rats, the
selective ET-A receptor blocker BQ-123 attenuated arrhythmias only
at the lowest dose, while signiﬁcantly increasing the incidence of irre-
versible VF at higher doses (Garjani et al., 1995).
Our group has recently observed that ET receptor blockade has
beneﬁcial effects on microvascular ﬂow, enzymatic infarct size and
long-term otucome in patients with AMI (Adlbrecht et al., 2012;
Adlbrecht et al., 2014).
Arrhythmia followingmyocardial infarction is associatedwithworse
prognosis. Nonsustained ventricular tachycardias (nsVTs) represent an
independent predictor for mortality and late potentials are a widely
used electrophysiological risk stratiﬁcation tool after myocardial infarc-
tion (Makikallio et al., 1999; Denniss et al., 1986; Gomes et al., 2001;
Steinberg et al., 1992). Although somewhat reduced in sensitivity,
they remain an independent risk factor in the reperfusion era (Bauer
et al., 2005).
In the present study, we evaluated safety and feasibility of ET-A
receptor blockade using the ET-A receptor antagonist BQ-123 using a
predeﬁned combined endpoint consisting of the occurrence of nsVT,
late potentials or both.
Materials and methods
Patients and inclusion criteria
One hundred seventeen men or post-menopausal women aged
18 years and above with posterior or inferior wall STE-ACS were
screened for eligibility between 2007 and 2009. 57 patients were ran-
domized (Adlbrecht et al., 2012). Three protocol violations occurred in
patients who were included into the study despite an onset of pain
more than 12 h ago. All three were in the placebo arm. Importantly,
all patients had either TIMI 0 or 1 coronary ﬂow in the infarct
related coronary artery before insertion of the guide-wire (Adlbrecht
et al., 2011).
Immediately prior to PCI, all patients received unfractionated hepa-
rin to reach an activated clotting time of 300 s, 500mg of acetylsalicylic
acid and 600 mg of clopidogrel.
Of the 57 patients enrolled in this randomized, placebo controlled,
double-blind study, 30 patients received 24-hour electrocardiograms
(ECG) and were included in the electrophysiologic substudy with a
predeﬁned primary endpoint. Patients who were included early during
themain trial did not receive Holter recordings, as the electrophysiologic
substudy was initiated at a later time-point.
Study protocol
The study was approved by the ethics committee of the Medical
University of Vienna and the Austrian Federal Ofﬁce for Safety in Health
Care (AGES) and was conducted in accordance with the Declaration
of Helsinki. After informed consent had been obtained, patients
were randomly assigned to either active treatment or placebo in a
double-blind fashion. Patients were randomized to receive BQ-123
(Clinalfa, Läufelﬁngen, Switzerland) dissolved in 50 mL of 0.9% NaCl at
400 nmol/min intravenously or placebo (NaCl) over 60 min, initiated
immediately before guidewire insertion (Adlbrecht et al., 2011).
Study drug dosing was based on published data showing that intra-
venous applications of BQ-123 above 300 nmol/min had reproducible
systemic effects and that dosages of 1000 nmol/min lowered systemic
blood pressure (Spratt et al., 2001).
Short-term administration was chosen to cover the crucial phase of
reperfusion during which the largest myocardial endothelin burden
has been found (Tonnessen et al., 1995). This also avoids side effects
(e.g. liver function impairment) of long-term endothelin receptor
antagonism (Hoeper, 2009). It was shown that intra-venous adminis-
tration of BQ-123 for 15 min induced hemodynamic effects for up to4h (Spratt et al., 2001), indicating an effect beyond its plasma half-life.
It is therefore plausible that direct effects are measurable at two days
when the ﬁrst recording was conducted. These inﬂuences on
inﬂammation, remodeling and microvascular function are possible
explanations for long-lasting effects.
Concomitant medical therapy was given according to standard of care.
Study procedure
Twenty-four hour Holter recordings (Del Mar Avionics, Del Mar
Medical Systems, Irvine, CA) were performed on two occasions, during
index hospitalization and at 6–8 weeks, to assess both immediate and
delayed effects of ET receptor blockade. Analysis was performed by
experienced physicians blinded to the trial randomization.
Study endpoints
The primary endpoint of this electrophysiologic substudy was
the presence of nsVT (deﬁned as a tachyarrhythmia originating
from the ventricles for a duration of b30 s), late potentials or both
at 6–8 weeks after STE-ACS (Exner et al., 2007).
In addition to the Holter recordings at follow-up, recordings were
also performed in the subacute phase of STE-ACS during the initial hos-
pital stay in order to account for both potential immediate and delayed
effects of the study drug.
Late potentials increase in prevalence at 7 to 10 days after AMI and
remain stable thereafter (Kuchar et al., 1986). Consequently, the time-
point for the predeﬁned primary study endpoint consisting of the
presence of nsVT, late potentials or both was chosen to be 6–8 weeks
after STE-ACS and the presence of nsVT in the Holter ECG recorded dur-
ing the index hospitalization alone served as a secondary endpoint.
Other secondary endpoints were the heart rate variability (HRV) pa-
rameter standard deviation of normal-to-normal intervals (SDNN) and
routinely assessed ECG variables, including ventricular extrasystoles
(VES), supraventricular extrasystoles (SVES) and sustained ventricular
tachycardia (sVT) runs, deﬁned as a tachyarrhythmia originating from
the ventricles for a duration of N30 s.
Statistical analysis
Fisher's exact test was used for evaluation of the primary study
endpoint. Continuous outcome measures are expressed as median
(25th–75th percentile) and the Mann–Whitney U test was used for
comparison between the two treatment groups. A p-value of b0.05
was considered as indicating statistical signiﬁcance.
Results
Patient population
Of the 30 patients in whom Holter recordings were available, 14
were randomized to receive placebo and 16 were assigned to receive
peri-interventional BQ-123. Median patient age was 61 (51–71) years,
and 7 patients (23%) were female. The ischemic time, deﬁned as the
period fromonset of chest pain toﬁrst balloon inﬂation or thrombectomy,
was 4 (2.5–5.6) hours. Left ventricular ejection fraction of patients in the
two treatment arms at baseline was comparable. Patient characteristics
are presented in Table 1.
Primary endpoint
At 45 days after AMI, no difference in the occurrence of late poten-
tials, nsVT or both was observed between the patients randomized to
receive either BQ-123 or placebo (0/16 (0%) vs. 1/14 (7%), p = 0.467).
Late potentials could be detected in only one patient. This patient had
been randomized to the placebo group.
Table 1
Patient clinical characteristics.
Therapy Control BQ-123 p-value
Age (years) 65 (52.8–72.5) 55.5 (50.8–71.8) 0.755
Male n (%) 12 (86%) 11 (69%) 0.399
Ischemic time (hours) 4.25 (2.25–5) 4 (2.5–6.25) 0.675
IRA 0.642
RCA n (%) 11 (79%) 14 (88%)
CX n (%) 3 (21%) 2 (12%)
CKmax (U/L) 2261 (1607–3139) 1371 (828–2081) 0.138
Hypertension n (%) 11 (79%) 9 (56%) 0.260
Hyperlipidemia n (%) 13 (93%) 12 (75%) 0.336
Diabetes mellitus n (%) 3 (21%) 1 (6%) 0.315
Current smoker n (%) 5 (36%) 10 (63%) 0.272
On dual antiplatelet therapy 14 (100%) 16 (100%) 1
On beta-blocker n (%) 14 (100%) 15 (94%) 1
On ACE inhibitor 12 (86%) 15 (94%) 0.586
On lipid lowering therapy 14 (100%) 15 (94%) 1
LVEF (%) 54 (50.8–61.5) 55.5 (52–59) 1
IRA: infarct related coronary artery, RCA: right coronary artery, CX: circumﬂex coronary
artery, CKmax: peak creatine kinase value, ACE: angiotensin converting enzyme, and
LVEF: left ventricular ejection fraction. Values are median (25th–75th percentile) or
number (percent) respectively. Percentages are rounded values.
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In the acute phase of myocardial infarction one patient experienced
asystole following PCI. The sinus pause occurred 2 min after the start
of BQ-123 infusion and was treated by 0.5 mg of intra-arterial atropine
to which the patient responded promptly, no further treatment was
necessary. Another patient experienced a ventricular tachycardia and
was re-admitted to the hospital — both patients had been randomized
to receive BQ-123. The need for peri-interventional atropinewas similar
in the BQ-123 treated group compared to the placebo group (8 (50%)
versus 8 (57%), p = 0.730).
At 2 days after AMI, Holter recordings revealed no difference regard-
ing the presence of nsVT (1 (7.15%) in the BQ-123 group vs. 0 (0%) in the
placebo group, p = 0.517) or sVT (1 (7.15%) vs. 0 (0%), p = 0.517).
The total number of SVES per 24 h recording was signiﬁcantly
increased in the BQ-123 treated group at both time-points: 2 days
(45 (17–165) vs. 11 (5–72), p = 0.025) and 45 days (105 (37–216)
vs. 11 (3–98), p = 0.037, Fig. 1).
Grouping for N100 SVES yielded no signiﬁcant difference at either
time-point (5 patients in the BQ-123 group at 2 days vs. 2 in the placeboFig. 1. Box plot presenting the total number of supraventricular extrasystoles (SVES) per
24 h recording during the index hospitalization and at post-discharge follow-up.treated group, p = 390; and 7 vs. 2 at 45 days, p = 0.208). There was
no signiﬁcant difference in the total number of VES at either time-
point (p = 0.595 and p = 0.311, respectively).
We classiﬁed the patients according to their beta-blocker dosage
(no beta blocker, 1–49% of target dose according to guidelines, 50–99%
of target dose and 100% target dose). After applying Spearman's rho,
we found no correlation between beta-blocker dosage and the
occurrence of SVES (r = 0.075, p = 0.721). There was no signiﬁcant
difference in the occurrence of supraventricular tachycardia.
No third-degree atrioventricular (AV) block occurred in any patient.
Second-degree AV block type Mobitz 1 occurred in two patients, one in
the treatment group and one in the placebo group. Both events occurred
twodays after AMI during the night. Seconddegree-AVblock typeMobitz
2 occurred in one patient randomized to receive BQ-123 three days after
the event. Pacemaker implantation was performed in this patient.
Two patients randomized to receive BQ-123 experienced episodes of
atrial ﬁbrillation (AF). One patient's Holter recording at two days after
AMI showed AF from the beginning of recording in themorning, lasting
for 7 h, converting spontaneously into sinus rhythm at around 3 p.m.
In the second patient, AF occurred at 11:20 a.m., preceded by isolated
premature ventricular contractions and one single premature supra-
ventricular contraction. One patient in the treatment group developed
a sinoatrial block.
Episodes of bradycardia were found in two patients in the treatment
group. Detailed electrocardiographic results of the follow-up are
presented in Table 2.
Discussion
This is the ﬁrst trial assessing the electrophysiological effects of
short-term systemic ET-A receptor blockade in patients with STE-ACS
undergoing primary PCI. While animal studies provided conﬂicting
results regarding the effect of ET receptor blockade on infarct size, or
their antiarrhythmic potential, the current electrophysiologic sub-
study suggests that the short-term use of BQ-123 in this setting is safe.
In a murine model of myocardial infarction, a decrease in the inci-
dence of VF and infarct size andmortality fromVF episodeswas demon-
strated for animals under ET-A receptor blockade (Baltogiannis et al.,
2005). In patients with STE-ACS treated with an ET-A receptor blocker
our group recently found an improvement in microvascular perfusion,
a decrease in the enzymatic infarct size and an increase in left ventricu-
lar ejection fraction after 6 months (LVEF) of 63% vs. 59% (p = 0.047)
(Adlbrecht et al., 2012). Infarct size, measured by both serum enzyme
levels and MRI, and LVEF are known to be predictors of ventricular
arrhythmia after AMI (Roberts et al., 1975; Crawford et al., 2010).
Apart from a potential direct beneﬁt of the blockade of pro-arrhythmic
effects of ET-1, this could be another mechanism contributing to the
lower incidence of ventricular arrhythmias reported in some studies
(Alberola Aguilar et al., 2000; Baltogiannis et al., 2005).Table 2
Electrocardiographic results.
BQ-123 Placebo p-value
Average heart rate (bpm) 68 (62–78) 64 (63–74) 0.936a
P-wave width (ms) 119 (109–127) 114 (100–124) 0.792a
PQ interval (ms) 165 (148–180) 162 (152–182) 0.719a
QRS duration (ms) 99 (90–109) 94 (92–96) 0.200a
QTc (ms) 420 (407–433) 428 (398–443) 0.434a
ST-segment changes
Elevation n (%) 7 (47%) 6 (55%) 0.691b
Depression n (%) 4 (27%) 0 (0%) 0.091b
bpm: beats per minute, ms: millisecond, QTc: QT interval corrected for heart rate. Values
are median (25th–75th percentile) or number (percent) respectively. Percentages are
rounded values.
a Fisher's exact test.
b Wilcoxon test.
433C. Adlbrecht et al. / Life Sciences 118 (2014) 430–434Conversely, various doses of the ET-A receptor blocker BQ-123were
compared in rats and a distinct pro-arrhythmic effect at higher doses
was observed (Garjani et al., 1995). In healthy human volunteers high
doses of BQ-123 (3000 nmol/min) led to a moderate increase in heart
rate (+18%) compared to the placebo group (Spratt et al., 2001). This
increase may be explained by the concurrent decrease in systemic
blood pressure.
The lack of consistency in data on the effect of ET receptor blockers in
AMImay be explained by species differences. However, more important-
ly, there exist vast differences in the ischemia (+/− reperfusion)
protocol as well as the timing and receptor selectivity of ET receptor an-
tagonists. In some animal models, the investigators applied the study
drug before coronary artery ligation, an approach of scientiﬁc interest,
however, an unrealistic setting in view of the clinical situation. It must
be emphasized that many of the published animal models of AMI are
not representative in the modern era of primary PCI, as in many cases
they represent ligation-only models. This resulted in relatively large
infarct sizes and frequent arrhythmic complications, and might have
therefore led to an overestimation of the pro- or antiarrhythmic poten-
tial. Additionally, the patient population included into the present
study (Table 1)was treated quickly (mean ischemic time of 4 h) in a set-
ting of guideline recommended door-to-balloon times, optimal medical
therapy and frequent utilization of thrombectomy devices impacting
on short- and long-term outcome (Kalla et al., 2006; Adlbrecht et al.,
2010). As a result, one would expect to see very few arrhythmic compli-
cations in the ﬁrst place. This is supported by the fact that there were
no nsVT runs detected in the placebo group after 2 days. These consider-
ations provide an explanation for the lack of difference in the combined
endpoint between the two groups. Furthermore, no signiﬁcant changes
in routinely determined Holter ECG parameters were observed (Table 2).
Our pilot study revealed that a relatively high number of patients
would be necessary for a phase III study evaluating clinical efﬁcacy.
We want to therefore emphasize that this sub-study should be primar-
ily regarded as a safety and feasibility study.
When interpreting the discrepancies of animal data, it is of interest
that experiments in rats showed a decrease in ventricular ectopic
beats after treatment with BQ-123 but also after pre-treatment with
ET-1 itself (Sharif et al., 1998). SVES (or premature atrial contractions
(PACs)) were found to be predictors of AF (Perez et al., 2009).
At 2 days, short episodes of AF were recorded in two patients (both
BQ-123 treated), whereas there was no documented AF at 45 days.
While in-vitro experiments showed a strong arrhythmogenic effect of
ET-1 on rat atrialmyocytes (Mackenzie et al., 2002), no atrial ﬁbrillation
could be observed after intra-coronary infusion of ET-1 in a dog model
(Kiss et al., 2004). We found no effect on the development of AF
but an increase in SVES. This might be explained by the many different
systems that play a pathophysiologic role in this setting, including but
not limited to, atrial remodeling, inﬂammation, neurohumoral signaling
and electrophysiologic conduction. In a cohort of healthy individuals,
the occurrence of excessive supraventricular ectopic activity, deﬁned
as ≥30 supraventricular ectopic complexes per hour, increased the
risk for AF or stroke in a follow-up period of 6.3 years (Binici et al.,
2010). In the present study, a mean value of 1.87 PAC per hour at
two days and 4.62 at 45 days was observed in the treatment group.
Although this represents a statistically signiﬁcant difference compared
to placebo-treated patients, it may not be clinically relevant. In two
studies, one including patients after AMI and the other recruiting
patients without structural heart disease, N100 PACs per day were
established as a cutoff for prediction of a decrease in LVEF or of the
occurrence of AF or adverse cardiovascular events, respectively (Zoni
Berisso et al., 1988; Chong et al., 2012). After classifying our patients ac-
cording to this scheme, we found only a non-signiﬁcant trend towards a
higher occurrence of N100 PACs per day in the treatment group at both
time-points.
Infarct location is an important predictor of arrhythmic complica-
tions after AMI. Anterior infarct location is associated with an increasedrisk of ventricular tachycardia and patients are more prone to develop
AF (Jabre et al., 2011), whereas posterior infarcts increase the incidence
of AV blocks (Hreybe and Saba, 2009). Therefore, the inclusion of
patients with anterior infarct location is warranted for a subsequent
protocol assessing the complete spectrum of effects of ET-1 receptor
blockade in the setting of AMI.
TheHRV parameter SDNN, calculated as the standard deviation of all
normal beats during the recording, is a very well established prognostic
marker after AMI (Bigger et al., 1992). The highest mortality rates
were observed in patients with a SDNN of b70 ms (La Rovere et al.,
1998). ET-1 plasma levels were inversely correlated to SDNN in a pa-
tient population with coronary slow-ﬂow (Pekdemir et al., 2004).
Very recently, a positive correlation between SDNN and the quality of
life was reported in patients with chronic heart failure (Chrysohoou
et al., 2010). While the difference in SDNN in the present study did
not reach statistical signiﬁcance, it does show a trend towards higher
SDNN in the treatment group at the earlier time-point, leaving the
placebo-treated patients within the high-risk group. One may argue
that within 48 h after the infusion of BQ-123, its positive effects on
microvascular ﬂow and anti-inﬂammatory effects are ongoing.
Limitations
The study is limited by its small size, single center design and surro-
gate endpoints, as it was designed as a “proof-of-concept” study. How-
ever, the present study is a prospective sub-study of the randomized
clinical trial assessing the effects of ET-A receptor blockade in STE-ACS.
Patients with anterior wall myocardial infarctions were excluded for
safety reasons because of data suggesting adverse cardiac remodeling
in anterior infarctions after ET receptor blockade (Nguyen et al., 1998).
Conclusion
Based on the analysis of long-term ECG data, short-term administra-
tion of BQ-123 after AMIwas safe. Because of the small sample size, typ-
ical for a phase II study, no ﬁrm conclusion regarding antiarrhythmic
efﬁcacy of ET receptor blockade can be drawn.
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